Small molecules targeting JAKs-a new approach in the treatment of rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 52, Issue 8, 2013, Pages 1352-1357

  Feist, Eugen ^a   Burmester, Gerd R ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Fostamatinib; Janus kinase; Rheumatoid arthritis; Tofacitinib

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BARICITINIB; CP 690550D; CYCLOSPORIN A; GLPG 0634; JANUS KINASE; JANUS KINASE INHIBITOR; METHOTREXATE; PLACEBO; TOFACITINIB; UNCLASSIFIED DRUG; VX 509;

ARTICLE; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; HUMAN; IC 50; MONOTHERAPY; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; URINARY EXCRETION;

FOSTAMATINIB; JANUS KINASE; RHEUMATOID ARTHRITIS; TOFACITINIB;

ADMINISTRATION, ORAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE III AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FORECASTING; GERMANY; HUMANS; JANUS KINASES; MALE; MAXIMUM TOLERATED DOSE; MOLECULAR TARGETED THERAPY; OXAZINES; PIPERIDINES; PROGNOSIS; PYRIDINES; PYRIMIDINES; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84879806081     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes417     Document Type: Article

References (15)

1. Flanagan ME, Blumenkopf TA, Brissette WH et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem 2010;53:8468-84.
2. Fox DA. Kinase inhibition-a new approach to the treatment of rheumatoid arthritis. N Engl J Med 2012;367:565-7.
3. Changelian PS, Flanagan ME, Ball DJ et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003;302:875-8.
4. Kremer JM, Bloom BJ, Breedveld FC et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009;60:1895-905.
5. Tanaka Y, Suzuki M, Nakamura H et al. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 2011;63:1150-8.
6. Karaman MW, Herrgard S, Treiber DK et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26:127-32.
7. Meyer DM, Jesson MI, Li X et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 2010;7:41.
8. Advisory Committee Meeting Tofacitinib for the Treatment of Rheumatoid Arthritis (NDA 203214). Briefing document, May 9, 2012. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM302960.pdf.
9. Fleischmann R, Kremer J, Cush J et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012;367:495-507.
10. van Vollenhoven RF, Fleischmann R, Cohen S et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508-19.
11. van Vollenhoven RF, Fleischmann RM, Cohen SB et al. Effects of tofacitinib (cp-690,550), an oral Janus kinase inhibitor, or adalimumab on patient-reported outcomes in a Phase 3 study of active rheumatoid arthritis. Poster EULAR 2012, Berlin. Abstract THU0151.
12. Burmester GR, Blanco R, Charles-Schoeman C et al. and on behalf of the ORAL Step investigators. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013. pii: S0140- 6736(12)61424-X.
13. Fleischmann R. Dose ranging study of VX-509, an oral selective JAK3 inhibitor, as monotherapy in patients with active rheumatoid arthritis (RA). ACR2011. Abstract L3.
14. Keystone E, Taylor P, Genovese M et al. 12-Week results of a phase 2B dose-ranging study of LY3009104 (INCB028050), an oral JAK1/JAK2 inhibitor, in combination with traditional DMARDS in patients with rheumatoid arthritis, EULAR 2012, Berlin. Abstract LB0005.
15. Vanhoutte FP, Mazur M, Namour F. et al. Efficacy and safety of GLPG0634, a selective JAK1 inhibitor, after short-term treatment of rheumatoid arthritis; results of a phase IIA trial. EULAR 2012, Berlin. Abstract OP0263.